Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at Piper Sandler

Piper Sandler began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price objective on the stock.

Several other brokerages have also issued reports on MNPR. Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright boosted their price objective on Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $25.35 on Friday. The firm has a market capitalization of $133.80 million, a PE ratio of -12.87 and a beta of 1.23. The stock’s fifty day moving average is $21.84 and its 200 day moving average is $10.79. Monopar Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. Equities analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the stock in a transaction dated Monday, October 28th. The stock was purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.